Novo Nordisk, the Danish pharmaceutical company, has established itself as a pioneer in diabetes treatment since its founding in 1923 and is increasingly expanding into other health areas. With a clear focus on innovation and research, the company has developed into a global market leader that improves the quality of life for millions of patients worldwide.

The origins of Novo Nordisk trace back to the founding of the Nordisk Insulin Laboratory, one of the first companies to produce insulin on a large scale. This groundbreaking work laid the foundation for the treatment of diabetes, which was then considered an incurable disease. The merger of Nordisk and Novo Industri in 1989 created the present-day Novo Nordisk, further solidifying its position in the global healthcare market.

The company has since been a leader in the development of insulin products and innovative therapies for chronic metabolic diseases. Particularly in the area of diabetes, Novo Nordisk has made significant contributions with products such as insulin analogs and GLP-1 agonists. Thanks to continuous investments in research and development, the company has been able to expand its global market leadership, according to Statista.

An outstanding example of product portfolio diversification is Ozempic, a GLP-1 analogue for the treatment of type 2 diabetes, which is enjoying international success. The active ingredient semaglutide not only regulates blood sugar levels but also induces a feeling of satiety, making the medication increasingly popular as a weight loss aid. The related medication Wegovy, also based on semaglutide, was approved in Germany in 2023 for the treatment of obesity and is receiving great acclaim.

In addition to diabetes, Novo Nordisk is also engaged in the areas of hemophilia, growth hormone therapy, and obesity. With a clear commitment to global healthcare, the company works closely with governments and health organizations to improve access to essential medications.